title: Temsirolimus controlled metastatic advanced renal cell carcinoma for over 4 years: a case study.
abstract: We present a case report of long-term response with temsirolimus in cytokine refractory metastatic renal cell carcinoma (RCC). A 74-year-old Japanese man was diagnosed with advanced RCC in November 2007 and enrolled in a phase II study to examine the safety and efficacy of temsirolimus in East Asian patients with metastatic RCC. He achieved a partial response 12 months after starting treatment with temsirolimus followed by stable disease for 39 months. The most notable toxicity was grade 3 pericardial effusion, which gradually increased 2 years after treatment start until discontinuation of the trial resulting in pericardial tamponade, grade 3 hypoxia associated with chronic obstructive pulmonary disease (COPD), which he had before the trial, and latent interstitial pneumonia. The cease of temsirolimus led to improvement of interstitial pneumonia while the target lesion progressed. He died of progressive COPD and latent interstitial pneumonia 4 months after discontinuing temsirolimus. To our knowledge, he lived the longest in East Asian populations since starting temsirolimus.
authors.affiliation: Department of Urology, Hamamatsu University School of Medicine, 1-20-1 Higashi-ku, Handayama, Hamamatsu, Shizuoka 431-3192, Japan. ttakayam@hama-med.ac.jp
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Takayama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Furuse
authors.forename: Fumitake
authors.initials: F
authors.lastname: Kai
authors.forename: Takayuki
authors.initials: T
authors.lastname: Sugiyama
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Ozono
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; C401859:temsirolimus; D020123:Sirolimus
references.citation: AJR Am J Roentgenol. 2004 Dec;183(6):1619-28
references.pmid: 15547201
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1061-8
references.pmid: 20100962
references.citation: Neuro Oncol. 2012 Dec;14(12):1511-8
references.pmid: 23099651
references.citation: Biochem Pharmacol. 2012 May 1;83(9):1146-58
references.pmid: 22285225
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1286-90
references.pmid: 18316545
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: J Clin Oncol. 2004 Mar 1;22(5):909-18
references.pmid: 14990647
references.citation: J Clin Oncol. 2010 May 1;28(13):2144-50
references.pmid: 20368553
references.citation: Jpn J Clin Oncol. 2012 Sep;42(9):836-44
references.pmid: 22844126
references.citation: J Cancer Res Clin Oncol. 2012 Jun;138(6):907-16
references.pmid: 22322364
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references.pmid: 19487381